American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

• Published in: The American journal of gastroenterology Vol. 113; no. Suppl 2; pp. 1 - 18
• Main Authors: Ford, Alexander C, Moayyedi, Paul, Chey, William D, Harris, Lucinda A, Lacy, Brian E, Saito, Yuri A, Quigley, Eamonn M M
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.06.2018
• Subjects: Anti-Bacterial Agents - therapeutic use; Antidepressive Agents - therapeutic use; Behavior Therapy; Constipation - drug therapy; Diarrhea - drug therapy; Diet; Dietary Fiber - administration & dosage; Dietary Fiber - adverse effects; Dietary Supplements; Disease management; Exercise; Gastroenterology; Humans; Irritable bowel syndrome; Irritable Bowel Syndrome - therapy; Parasympatholytics - therapeutic use; Plant Oils - therapeutic use; Prebiotics; Probiotics - therapeutic use; Randomized Controlled Trials as Topic; Synbiotics
• ISSN: 0002-9270; 1572-0241
• DOI: 10.1038/s41395-018-0084-x

Irritable bowel syndrome (IBS) is the most prevalent of the functional gastrointestinal disorders (FGIDs). Current estimates are that IBS affects up to 10–12% of adults in North America. Although it can affect all individuals regardless of age, creed, or gender, IBS is more common among women and is most commonly diagnosed in younger individuals (age <50). The goal of this document, therefore, is to provide an updated, evidence-based document on the therapy of this common and, at times, debilitating disorder.